Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Local vs Systemic IGF-1: The Research Design Implication

A key experimental consideration in IGF-1 LR3 research is the distinction between local intramuscular injection (mimicking locally produced muscle IGF-1) and systemic administration (mimicking GH-stimulated hepatic IGF-1 release). These routes produce differen

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • A key experimental consideration in IGF-1 LR3 research is the distinction between local intramuscular injection (mimicking locally produced muscle IGF-1) and systemic administration (mimicking GH-stimulated hepatic IGF-1 release). These routes produce different spatial patterns of IGF-1R activation and different hypertrophic responses:
  • Local intramuscular injection produces site-specific hypertrophy — the injected muscle shows greater hypertrophy than contralateral control muscles. This local specificity reflects the concentration gradient of IGF-1 LR3 at the injection site exceeding the levels reached systemically. This makes intramuscular IGF-1 LR3 a useful tool for unilateral hypertrophy models and studies of local vs systemic anabolic signalling.
  • Systemic administration produces a bilateral, whole-body anabolic effect — all muscles are exposed to elevated IGF-1 LR3 levels. This is appropriate for studies of systemic GH/IGF-1 axis effects, muscle wasting reversal in cachexia or atrophy models, or whole-body anabolic pharmacology.